Results 41 to 50 of about 45,662 (251)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Brazilian Journal of Medical and Biological Research, 2023
The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR ...
A.S. Ryazanov, E.V. Shikh, M.V. Makarovskaya, A.A. Kudryavtsev   +3 more
doaj   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
], Akshay S. Desai, Barry M. Massie, Claudio Borghi, for the ATMOSPHERE Committees Investigators [, Georgia Tarnesby, Henry Krum, John J.V. McMurray, Kenneth Dickstein, Lars V. Køber, M. Atif Ali, Nicola Greenlaw, Qing Shao, Scott D. Solomon, William T. Abraham, Yanntong Chiang   +15 more
core   +5 more sources

Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation

International Journal of Cardiology: Heart & Vasculature, 2019
Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard, Antoine Da Costa, Romain Pierrard, Cécile Roméyer-Bouchard, Jean Baptiste Guichard, Karl Isaaz   +5 more
doaj   +1 more source

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Рациональная фармакотерапия в кардиологии, 2023
Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with ...
A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev   +4 more
doaj   +1 more source

What can we learn from SOCRATES: more questions than answers? [PDF]

, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice

European Journal of Histochemistry, 2022
Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan, Hong Zhu, Yingxia He, Qinqin Wu, Xiaoyu Duan   +4 more
doaj   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of sacubitril–valsartan in women with preserved ejection ...
Zahra N. Sohani, Hassan Behlouli, Cristiano Soares de Moura, Michal Abrahamowicz, Louise Pilote   +4 more
doaj   +1 more source